Xiaozheng Kang

Xiaozheng Kang

Auto-generated profile, based on publicly available information

Xiaozheng Kang

Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
XWXin Wang
Xin Wang
XKXiaozheng Kang
Xiaozheng Kang
RZRuixiang Zhang
Ruixiang Zhang
LXLiyan Xue
Liyan Xue
JXJiaqi Xu
Jiaqi Xu
YLYin Li
Yin Li
Purpose: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients and Methods: Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate. Results: Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS. Conclusions: Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.

26 November 2014 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
QSQi Shi
Qi Shi
XKXiaozhen Kang
Xiaozhen Kang
FSFa-Nian Shi
Fa-Nian Shi
JDJinxiang Dong
Jinxiang Dong
Zn10(Im)20·4DBF has an unprecedented zeolitic topology and features 10 crystallographically independent Zn atoms and an unusual 4-connected 10-nodal net.

21 November 2016 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
YLYao Lin
Yao Lin
LSLuyan Shen
Luyan Shen
HFHao Fu
Hao Fu
BDBin Dong
Bin Dong
HYHe-Li Yang
He-Li Yang
KCKeneng Chen
Keneng Chen

1 September 2021 in Annals of Esophagus
Verified
Journal Article
Open access
PDF file
XKXiaozheng Kang
Xiaozheng Kang
JQJianjun Qin
Jianjun Qin
RZRuixiang Zhang
Ruixiang Zhang
ZWZhen Wang
Zhen Wang
QZQingfeng Zheng
Qingfeng Zheng
KMKenneth L. Meredith
Kenneth L. Meredith
2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer


15 November 2024
Verified
Other
Open access
XWXin Wang
Xin Wang
XKXiaozheng Kang
Xiaozheng Kang
RZRuixiang Zhang
Ruixiang Zhang
LXLiyan Xue
Liyan Xue
JXJiaqi Xu
Jiaqi Xu
YLYin Li
Yin Li
Supplementary Figure 5. Results of univariate analyses for overall survival